BioInvent International AB (publ) (BOVNF)

USD 4.7

(-29.11%)

Market Cap (In USD)

309.28 Million

Revenue (In USD)

71.46 Million

Net Income (In USD)

-330.3 Million

Avg. Volume

526.00

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
4.7-4.7
PE
-8.55
EPS
-0.55
Beta Value
0.38
ISIN
SE0015244520
CUSIP
-
CIK
-
Shares
65804400.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Martin Welschof Ph.D.
Employee Count
-
Website
https://www.bioinvent.com
Ipo Date
2013-09-03
Details
BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, Japan, and internationally. Its lead drug candidate is BI-1206 for the treatment of non-Hodgkin lymphoma and solid tumors. The company also develops tumor associated myeloid cells; cancer-associated regulatory T cells, which modulate the immune system; BT-001 in solid tumors; and BI-1808 and BI-1910, which are anti-TNFR2 antibodies for the treatment of solid tumors and cutaneous T-cell lymphoma. It has a strategic collaboration with Pfizer Inc. for the development of antibodies against tumor-associated myeloid cells; partnership and collaboration with Transgene to co-develskylinop multi-functional oncolytic viruses for treatment of solid tumors; and collaboration and supply agreement with Merck for the clinical development of BI-1808. The Company was incorporated in 1996 and is based in Lund, Sweden.